Presbyopia Therapies is developing LiquidVision Eye Drops to treat presbyopia, a large global market affecting most people over age 50. The drops aim to improve near vision without distance vision blur for 5+ hours after a single daily dose. Currently, the main treatment options are reading glasses or contact lenses. A phase 2a trial in 2016 showed the drops improved uncorrected near vision versus placebo. A phase 2b trial beginning in Q2 2017 aims to demonstrate a 30 minute onset and 5+ hour duration with a 3-line improvement in near vision. The company hopes to create a new global market category for the daily treatment of presbyopia.

1. Presbyopia Therapies
LiquidVision Eye Drops

2. Summary
• Presbyopia Market
- Large global market (most people over age 50 have it).
100M+ presbyopes in US alone.
• Limited Treatment Options
- Primarily reading spectacles (invented late 1200s) or
contact lenses (invented late 1800s)
• Significant Global Business Opportunity
- Create a new global market category (Lifestyle
Enhancement) for the daily treatment of presbyopia
• Regulatory Status
- Phase 2a pilot trial in 2016
- Phase 2b clinical trial in 2017
2

3. Presbyopia Therapies
• Product Overview:
- Improves near vision without distance vision blur
- Daily use (or as needed) for Lifestyle Enhancement
- Fast acting, 30 minute onset, with 5+ hour duration
- Binocular, not monovision
- Rx drug, patient pay (elective)
- Compliments current treatment options (not a
permanent replacement for reading glasses or other
options)

4. 2.3 mm
no pinhole
TYPICAL MIOTIC (PUPIL CONSTRICTOR)
DISTANCE BLUR, IMPROVED NEAR
High accommodation

5. BOTH PINHOLE OPTICS & MODERATE ACCOMMODATION FOR IMPROVED BINOCULAR NEAR & DISTANCE VISION
1.5 to 1.9 mm
Moderate
accommodation
STRONG PINHOLE EFFECT
LIQUIDVISION Eye Drops:
Aceclidine (miotic)/Tropicamide (cycloplegic)
(No Pilocarpine)

6. FDA/Regulatory Status
• Phase 2a Pilot trial in 2016 (dosing, safety and efficacy)
- Improvement in uncorrected near visual acuity vs. placebo at multiple near distances and over
multiple times points following a single dose
- Drug was well tolerated as no serious adverse events
- Potentially higher strength formulation with an enhanced protocol will be evaluated as part of phase
2b
• Phase 2b Clinical Trial in 2017
- Goals: 30 min onset; 5+ hour duration with near vision improvement of 3 lines
- Clinical trial begins Q2, 2017
- Top line data available Q4, 2017

7. Presbyopia Therapies Team
• Co-Founders
- Lee Nordan, MD (deceased)
- Jerry Horn, MD
- Jim McCollum
• Medical Advisory Board and MD consultants
- Steven Dell, MD Robert Osher, MD
- Terry Kim, MD John Doane, MD
- Coby Kraff, MD David Leach, MD
- Marc Odrich, MD David Castillejos, MD

8. Presbyopia Therapies
LiquidVision Eye Drops